1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Dali Pharmaceuticalco.,Ltd

Dali Pharmaceuticalco.,Ltd

603963.SS
Dali Pharmaceuticalco.,LtdCN flagShanghai Stock Exchange
1.18
CNY
- -
- -
259.25MMarket Cap

Total Valuation

Dali Pharmaceuticalco.,Ltd carries a market capitalization of 259.25M, placing it among publicly traded companies globally. Its enterprise value stands at 483.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap259.25M
Enterprise Value483.48M

Share Statistics

Dali Pharmaceuticalco.,Ltd currently has 219.70M shares outstanding.

Shares Outstanding219.70M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 10.89, and the price-to-book ratio stands at 3.18.

PE RatioN/A
PS Ratio10.89
PB Ratio3.18
P/TBV Ratio2.05
P/FCF Ratio157.70
P/OCF RatioN/A

Enterprise Valuation

EV / Sales7.84
EV / EBITDAN/A
EV / EBITN/A
EV / FCF89.45

Financial Position

Dali Pharmaceuticalco.,Ltd maintains a current ratio of 3.53, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.49, indicating elevated leverage, while an interest coverage ratio of -26.08 demonstrates limited ability to service its debt obligations.

Current Ratio3.53
Quick Ratio2.69
Debt / Equity5.49
Debt / EBITDA-0.70
Interest Coverage-26.08

Financial Efficiency

Return on Equity (ROE)-10.93
Return on Assets (ROA)-5.33
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.09

Taxes

Income Tax1.41M
Effective Tax RateN/A

Stock Price Statistics

Dali Pharmaceuticalco.,Ltd's stock has declined approximately -84.16107% over the past 52 weeks. The 50-day moving average sits at 1.57, while the 200-day moving average is 2.74.

Beta (5Y)N/A
52-Week Price Change-84.16107%
50-Day Moving Average1.57
200-Day Moving Average2.74
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Dali Pharmaceuticalco.,Ltd generated 61.64M in revenue and converted that into -24.38M in net income, yielding earnings per share of -0.11. EBITDA reached -28.20M, while operating income came in at -28.20M.

Revenue61.64M
Gross Profit4.67M
Operating Income-28.20M
Pretax Income-22.96M
Net Income-24.38M
EBITDA-28.20M
EBIT-28.20M
Earnings Per Share (EPS)-0.11

Balance Sheet

Dali Pharmaceuticalco.,Ltd holds 207.69M in cash and equivalents against 19.84M in total debt, resulting in a net debt position of -197.18M. Total book value stands at 210.92M, with working capital of 195.97M providing operational flexibility.

Cash & Cash Equivalents207.69M
Total Debt19.84M
Net Debt-197.18M
Equity (Book Value)210.92M
Book Value Per Share0.96
Working Capital195.97M

Cash Flow

After subtracting -4.26M in capital expenditures, free cash flow totaled -4.26M - equivalent to -0.02 per share.

Operating Cash FlowN/A
Capital Expenditures-4.26M
Free Cash Flow-4.26M
FCF Per Share-0.02

Margins

Dali Pharmaceuticalco.,Ltd operates with a gross margin of 7.58, reflecting its pricing power and cost economics. The operating margin of -45.75 and net profit margin of -39.55 provide insight into operational efficiency.

Gross Margin7.58
Operating Margin-45.75
Pretax Margin-37.25
Profit Margin-39.55
EBITDA Margin-45.75

Dividends & Yields

The company's payout ratio of -4.28 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.00
Dividend YieldN/A
Payout Ratio-4.28
Shareholder Yield2.04
FCF Yield0.63

Stock Splits

Dali Pharmaceuticalco.,Ltd's most recent stock split took place on June 8, 2020 with a 10:13 split ratio.

Last Split Date6/8/2020
Split Ratio10:13

Scores

Dali Pharmaceuticalco.,Ltd posts an Altman Z-Score of 5.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.00